Home / Business and Economy / Biohaven Shares Plummet After FDA Pauses Epilepsy Drug Study

Biohaven Shares Plummet After FDA Pauses Epilepsy Drug Study

10 Sep

Summary

FDA placed a partial clinical hold on Biohaven's epilepsy drug.
New patient enrollment is paused due to findings in rodent studies.
Biohaven's stock dropped significantly in premarket trading.

On Thursday, September 10, 2026, Biohaven announced a significant development regarding its experimental epilepsy drug. The U.S. Food and Drug Administration (FDA) has issued a partial clinical hold, effectively pausing the enrollment of new patients into the drug's trials.

This regulatory action stems from adverse findings identified in rodent studies related to the experimental treatment. The implications of these findings led to a notable market reaction, with Biohaven's stock price dropping more than 13% in premarket trading following the announcement.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.